Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172)
Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172)
复制标题
DOI：
10.1016/s0954-6111(99)90155-5
复制
发表时间：
1999-08-01
影响因子：
4.3
通讯作者：
Stanford, J
中科院分区：
文献类型：
--
作者：
Dlugovitzky, D;Bottasso, O;Stanford, J
两个小的。在阿根廷进行了一项安慰剂对照研究，在肺结核的常规化疗中加入热灭活分枝杆菌疫苗进行免疫治疗，共涉及40名艾滋病毒血清阴性患者。免疫治疗与1个月时AFB痰涂片阳性率降低和2个月时血沉下降幅度更大相关。在第一项研究中，接受免疫治疗的患者放射学改善较好(P<；0.05)。在第二项研究中，体重恢复和无氧时间在接受免疫治疗的患者中得到了改善(P<；0.05)。在治疗的第一个月，65 kDa和70 kDa热休克蛋白的免疫球蛋白水平在免疫治疗后出现了更大的下降(分别为P<；0.05和P<；0.001)。入院时血清细胞因子IL-4、IL-10、干扰素-γ和肿瘤坏死因子-α水平较对照组显著升高(P<0.001)。1个月后。免疫治疗组较单纯化疗组IL-4、IL-10和肿瘤坏死因子-α水平下降(P<0.001)，干扰素-γ水平升高(P=0.005)。这一结果与免疫治疗接受者转向TH1免疫学状态和临床益处是一致的。(C)1999 HarCourt出版有限公司。
Two small. placebo-controlled studies of immunotherapy with heat killed Mycobacterium vaccae added to routine chemotherapy for pulmonary tuberculosis, together involving 40 HIV seronegative patients, were carried out in Argentina. The immunotherapy was associated with reduced sputum smear positivity of AFB at 1 month and a greater reduction in ESR at 2 months. In the first study radiological improvement was better (P < 0.05) among immunotherapy recipients. In the second study, weight regain and time to become apyrexial were measured and were found to be improved amongst immunotherapy recipients (P < 0.05).In the first month of treatment the levels of IgG to the 65 kDa and 70 kDa heat-shock proteins showed greater falls following immunotherapy (P < 0.05 and P < 0.001, respectively). On admission serum cytokine levels of interleukins 4 and 10 (IL-4, IL-10), interferon gamma (IFN-gamma) and tumour necrosis factor alpha (TNF-alpha) were grossly raised in comparison with a matched control group (P < 0.001). After 1 month. Levels of IL-4, IL-10 and TNF-alpha fell (P < 0.001, P < 0.01 and P < 0.01, respectively) and levels of IFN-gamma rose more (P = 0.005) in immunotherapy recipients than in those receiving chemotherapy alone. The results are in accord with a switch towards a TH1 immunological status and clinical benefit for immunotherapy recipients. (C) 1999 Harcourt Publishers Ltd.